Skip Navigation


NDT Advance Access originally published online on July 25, 2008
Nephrology Dialysis Transplantation 2008 23(10):3353-3355; doi:10.1093/ndt/gfn401
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/10/3353    most recent
gfn401v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Alexandru, S.
Right arrow Articles by Plaza, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alexandru, S.
Right arrow Articles by Plaza, J. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Severe everolimus-associated pneumonitis in a renal transplant recipient

Simona Alexandru1, Alberto Ortiz1, Sonia Baldovi1, Jose Maria Milicua2, Elena Ruíz-Escribano2, Jesús Egido1 and Juan José Plaza1

1 Nephrology Unit 2 Intensive Care Unit, Fundación Jiménez Díaz-Capio, Universidad Autónoma, Madrid, Spain

Simona Alexandru, Nephrology Unit, Fundación Jiménez Díaz-Capio, Av Reyes Catolicos 2, 28040 Madrid, Spain. Tel: +34-9155-04940; Fax: +34-9155-42636; E-mail: salexandru{at}fjd.es, simona_amely{at}yahoo.com



  Abstract

Inhibitors of mTOR (mammalian target of rapamycin) are immunosuppressants with less nephrotoxic potential than calcineurin inhibitors and antiproliferative effects, which are advantageous in the case of malignancy. However, a series of adverse events has been reported with the first-generation mTOR inhibitor sirolimus that includes hypersensitivity-like interstitial pneumonitis. To our knowledge, only one case of a pneumonitis associated with everolimus in a heart transplant patient has been reported, and it was related to elevated trough blood levels. We report herein the first case of a kidney graft recipient who developed everolimus-associated pneumonitis with normal trough blood levels that was completely reversed after drug withdrawal.

Keywords: everolimus; pneumonitis; sirolimus; transplantation

Received for publication: 17. 3.08
Accepted in revised form: 24. 6.08


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.